06 November 2019
NICE prepares for updating the NICE Quality Standard on HMB, due for publication in 2020.
In preparation for a consultation on the draft quality standard, due to launch on 19 November 2019 and with an anticipated updated standard published in June 2020, NICE has published a topic overview on heavy menstrual bleeding. Alongside the existing core elements of the quality standard, NICE invited stakeholders to identify a maximum of five key areas for quality improvement. As these may feature in the quality standard, it is already worth keeping front-of-mind when engaging on HMB treatment.
Bayer has focus on the following three key areas:
- Provision of information for women about HMB and treatments;
- Management of HMB for women with no identified pathology; and
- Recognition of HMB as having a major impact on a women’s quality of life and ensuring that any intervention aims to improve this rather than focusing on blood loss.
For more information, please refer to the NICE Quality Standard Topic Overview on HMB